The exact reasons for the general resistance of cancer patients to checkpoint blockade therapy are still unclear and probably vary among different cancers, and preliminary studies have shown that resistance seems to be related to the tumor PD-L1 expression level and immune infiltration status 5-7. The gene discussed is CD274; the disease is cancer.